Results 11 to 20 of about 12,580 (199)

Favipiravir for treating COVID-19 [PDF]

Cochrane Database of Systematic Reviews, 2022
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to challenge the health workforce and societies worldwide. Favipiravir was suggested by some experts to be effective and safe to use in COVID-19.
Korula, Pritish, Alexander, Hanna, John, Jisha Sara, Kirubakaran, Richard, Singh, Bhagteshwar, Tharyan, Prathap, Rupali, Priscilla   +6 more
core   +5 more sources

Favipiravir‐induced bradycardia: A case report

Clinical Case Reports
Key Clinical Message The purpose of this case report is to reveal one of the cardiovascular side effects of favipiravir, sinus bradycardia. Abstract Favipiravir has emerged as a potential treatment for COVID‐19, with its antiviral properties showing ...
Alireza Kashefizadeh, Laya Ohadi, Farbod Amiri, Maryam Abdolmaleki, Vahid Eslami, Mehrdad Jafari Fesharaki   +5 more
doaj   +2 more sources

Favipiravir Inhibits Mayaro Virus Infection in Mice

Viruses, 2021
Mayaro virus (MAYV) is an emergent alphavirus that causes MAYV fever. It is often associated with debilitating symptoms, particularly arthralgia and myalgia.
Michèle Bengue, Ai-rada Pintong, Florian Liegeois, Antoine Nougairède, Rodolphe Hamel, Julien Pompon, Xavier de Lamballerie, Pierre Roques, Valérie Choumet, Dorothée Missé   +9 more
doaj   +2 more sources

Use of Favipiravir in Covid-19 Patients: A Narrative Review [PDF]

JPSCR: Journal of Pharmaceutical Science and Clinical Research
COVID-19 is an acute respiratory disease resulting from the infection of SARS-COV-2 viruses and causes high morbidity, which requires appropriate treatment targets. Favipiravir is an antiviral that selectively inhibits RNA-dependent RNA polymerase (RdRp)
Vitarani Dwi Ananda Ningrum, Annisa Fitria, Fadiyah Ulfa Hanur   +2 more
doaj   +2 more sources

The mechanism of resistance to favipiravir in influenza [PDF]

Proceedings of the National Academy of Sciences, 2018
Favipiravir is a broad-spectrum antiviral that has shown promise in treatment of influenza virus infections. While emergence of resistance has been observed for many antiinfluenza drugs, to date, clinical trials and laboratory studies of favipiravir have not yielded resistant viruses.
Goldhill, Daniel H, Te Velthuis, Aartjan JW, Fletcher, Robert A, Langat, Pinky, Zambon, Maria, Lackenby, Angie, Barclay, Wendy S   +6 more
openaire   +6 more sources

Dysregulated glycerophospholipid metabolism in amygdala may mediate favipiravir-induced anxiety-like behaviors in mice [PDF]

Frontiers in Pharmacology
Favipiravir, the first RNA polymerase inhibitor approved to treat resistant influenza, has been reported to be associated with central nervous system (CNS) side effects, particularly anxiety-like behavior; nevertheless, the underlying mechanism remains ...
Yuzhou Xiao, Chunqi Liu, Xiaojie Wang, Hongchun Li, Liang Wang, Kun Gou, Xingchen Liu, Xinqi Guan, Xia Zhou, Xiumei He, Yue Zhao, Lei Tao, Xiaodan Pan, Linhong Jiang, Yaxing Chen, Huan Liu, Yanping Dai, Qian Bu, Meng Qin, Ruiming Zhu, Bo Chen, Angelo D. Flores, Yinglan Zhao, Xiaobo Cen   +23 more
doaj   +2 more sources

STUDI EFEKTIVITAS DAN EFEK SAMPING FAVIPIRAVIR PADA PASIEN COVID-19 PNEUMONIA DI RUMAH SAKIT BHAYANGKARA SURABAYA [PDF]

JIIS: Jurnal Ilmiah Ibnu Sina, 2023
Favipiravir merupakan antivirus untuk pengobatan COVID-19 karena mekanisme kerja obat atau efektivitasnya yang baik pada pasien COVID-19 dengan atau tanpa pneumonia.
Rika Yulia, Fauna Herawati, Klara Rosjuita Hima, Ruddy Hartono, Puri Safitri Hanum   +4 more
doaj   +2 more sources

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study. [PDF]

Clin Pharmacol Ther
AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Rowland T, FitzGerald R, Challenger E, Dickinson L, Else LJ, Walker L, Hale C, Shaw V, Kelly C, Lyon R, Gibney J, Dhamani K, Irwin M, Enever Y, Tetlow M, Wood W, Reynolds H, Chiong J, Osanlou O, Pertinez H, Bullock K, Greenhalf W, Owen A, Lalloo DG, Jacobs M, Hiscox JA, Jaki T, Mozgunov P, Saunders G, Griffiths G, Khoo SH, Fletcher TE, AGILE CST‐6 Study Group.   +32 more
europepmc   +2 more sources

The effect of favipiravir on fracture healing

Acta Orthopaedica et Traumatologica Turcica
Objective: The aim of this study was to evaluate the effects of favipiravir on fracture healing. Methods: Forty-eight female rats which had a femur fracture with intramedullary Kirschner wire fixation performed were divided into 6 groups; 2 control groups (C1, C2) and 4 experimental groups (F1, F2, F3, F4).
Sabir, Mehmet Ali, Celik, Ahmet Onur, Demirtas, Elif Mercan, Copuroglu, Cem   +3 more
openaire   +5 more sources

Small Molecule Inhibition of Mononegavirales RNA Polymerases. [PDF]

J Med Virol
ABSTRACT The order Mononegavirales includes several non‐segmented negative‐sense RNA viruses that are significant human pathogens, whose transcription and replication depend on multifunctional RNA‐dependent RNA polymerase (L protein). Recent discoveries in cryo‐electron microscopy (cryo‐EM) have elucidated the structures of these polymerases and their ...
Cao CR, Mohammed M, Yang G, Wang D.
europepmc   +2 more sources